Rebirth of the God-level Xueba

The visit process that Yang Rui prepared for companies such as Zelecom was very short, but it was enough to let them know the working conditions of the laboratory.

This is also a very important point. The experimental data of third-rate laboratories are not credible, just like the articles of many unknown scholars in unknown universities, which are rarely cited. The main reason is credibility. Scholars read these articles mostly to provide a way of thinking. When they really need data, they will do it by themselves before rest assured.

The data obtained by deferiprone in the Huarui laboratory is very good, so Yang Rui asked them to understand the Huarui laboratory first.

As for specific data, etc., there is no need to release it.

What everyone else sees is a simple collection of data.

But these data sets are enough for representatives of various companies to ponder for a long time.

At the end of the visit, Yang Rui took Grace, Wei Zhenxue, Wang Xiaoyun and other members of the drug group, and friendly sent the representatives of each company out of the door.

Watching the cars start, and then slowly leave, Grace laughed a rare laugh.

Wei Zhenxue looked at Grace's smile inexplicably, and asked, "Do you like to watch car exhaust too?"

Wang Xiaoyun habitually helped Wei Zhenxue translate.

Grace frowned unclearly: "Also?"

Wei Zhen learned to understand the words, "oh" smiled, and said: "I don't mean that I like to look at car exhaust, I don't like to look at car exhaust, but Bao Si likes it. Have you heard the story of the lords of the beacon play? Women like to watch fireworks and the Great Wall..."

"Old Wei." Yang Rui was dumbfounded, and sighed: "How did you really provoke people?"

Wang Xiaoyun was also silly when she heard it, but she stopped translating and said: "Old Wei, thank you for not knowing English. Otherwise, you could smoke in the afternoon."

"What do you mean?" Wei Zhenxue didn't understand.

"Cremate your smoke." Wang Xiaoyun was stern.

Wei Zhenxue was not affected at all, and smiled: "Impossible. Our home rule is that people have to stop for seven days if they die. If I died today, you burned it for me today? You are too bad. Fortunately, it is not my wife. "

Wang Xiaoyun said angrily: "I'm a bad guy? You don't want to ask why you died?"

"No need, we are not afraid of death. Don't study chemistry if you are afraid of death, don't you think?" Wei Zhenxue made a resolute expression, matching the facial features on the big face, like a puppet army's death squad.

Grace looked at the two people who were speaking quickly, and asked Yang Rui in surprise, "They were talking to me just now, didn't they?"

"Yes."

"Why didn't you say it halfway through?"

"Um..." Yang Rui didn't know how to explain a story that was more amusing than a normal person.

"I did something wrong, right?" Grace felt that Yang Rui's expression was familiar, and said: "I often make people angry, it doesn't matter, you just tell me what went wrong."

"It's not your problem." Yang Rui didn't bother to explain, and said directly: "You just watched the people from Zelecom leave and laughed out. Why?"

"I'm thinking about how they will drive back after they have evaluated the prospect of removing iron ketones." Grace smiled softly again.

"The profit of deferiprone will not be too high, after all, there is deferoxamine."

"For a drug that has just been tested on animals, the most important thing is how much it can pass through clinical trials." Grace said, and said: "I hope you can choose a suitable company to sell it, not Choose the one with the highest offer."

"Yep?"

"Although the companies with the highest offer prices may be the most interested, this does not mean that they have the strongest execution capabilities." Grace said: "A suitable company may complete the clinical trial of deferiprone within two or three years. , An inappropriate company, it may take seven or eight years..."

"I understand, I will choose the most suitable company, even if it doesn't make money." Yang Ruiyi said righteously.

"How can you not make money?" Grace glanced at him and said: "I am the only medicinal chemist in your team, and you don't need salary. The total development time is no more than three months, even if you add your theoretical research time. , And it doesn't cost much, you will become a monopoly."

"That's not bad." Yang Rui smiled happily.

…

the next day.

Van Lundin also issued a similar exclamation: "The Chinese are really going to get rich."

Arnold also said with a calm face: "54 points are indeed a point for getting rich."

What they are doing is clinical drug candidate evaluation, which is to evaluate that a drug has a high probability of passing clinical trials.

Only drugs with a high probability of passing will enter clinical candidates and then have the opportunity to conduct clinical trials.

Different from ordinary people’s intuition, those drugs that may be effective in treating diseases do not have a strong advantage in the evaluation of clinical drug candidates. The reason is simple. There are many good drugs. You need to pass the review to make money. , What can't be passed, it's just a rainbow.

For any drug, getting a high score in the evaluation of clinical drug candidates means that it has great prospects. Companies such as Zeleca and Pfizer like the acquisition of drugs after the animal experiment stage.

They will spend tens of millions of billions to buy a drug, and then spend two or three times the price for clinical trials. Once successfully passed, they will be able to earn back all their previous efforts in one go.

It is also for this reason that three-quarters of the original drugs developed every year in countries around the world are developed on the targets of existing drugs.

Such original drugs, although they are also original, are not highly original, but they are safe.

They are cash cows that can safely make profits.

The more extreme example is antidepressants. The FDA has approved no less than 7 products, and each has achieved sales of more than $1 billion.

In any pharmaceutical company, "blockbuster" is an important capital, so that it can be met but not sought. In contrast, it is much simpler to make an original drug with the target as the target. UU reading www. uukanshu.cOM

Deferiprone is different, because the last seven active substances left by Yang Rui have good effects and their scores are very high, which greatly increases the chance of deferiprone through clinical trials.

As long as it can pass clinical trials and officially go on the market, how to sell is another matter.

According to Zelikang’s evaluation model, usually compounds with a score of 30 or more can be included in the list of clinical drug candidates, and a score of 40 or more is basically ranked in the forefront. There is no major problem, and clinical trials will definitely be carried out.

As for drugs with a score of 50 or more, there are not a few drugs each year.

Arnold did the calculations and determined that desferiprone had reached the 54 points standard.

"This guy has applied for too many patents." Arnold didn't know whether he was admired or angry.

If there is a chance, large pharmaceutical companies don't mind looting small companies by squatting patents.

For a drug whose annual sales may exceed 100 million yuan, and its value is over 1 billion or even tens of billions, large pharmaceutical companies can do everything.

Frankie personally checked the patent and said: "Yang Rui is still fighting a lawsuit now, so he must be very concerned about patent issues."

“I registered patents for intermediates, preparation methods, product patents, crystals, amorphous patents, and composition patents in one breath!” Arnold grumbled: “He also lacks a sense of security. If it’s done, it can’t give people any more trust.”

Frankie pondered the question of "trust" for a long time.